OPSUMIT^® (macitentan):
 The only ERA with 7-year survival estimates^1,2

In long-term follow-up of patients who were treated with OPSUMIT® 10 mg in the placebo-controlled study (n=242) and the open-label extension study (n=182), Kaplan-Meier estimates of survival at 1, 3, 5, and 7 years were 95%, 84%, 73%, and 63%, respectively. The median exposure to OPSUMIT® was 4.6 years.^1,2

Overall survival Kaplan-Meier curve for patients randomized to OPSUMIT® 10 mg in SERAPHIN and entered into the open-label extension study^1,2

Adapted from Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390. doi:10.1007/s12325-022-02199-x. Data presented are Kaplan-Meier survival estimates (95% CI).